No experience
Employment Type:
Job Category:
Summer Biology Intern - Protein Purification and...
(This job is no longer available)
Portola Pharmaceuticals | South San Francisco, CA
Grad Date

Not sure what types of jobs you are interested in?

Explore Jobs
Based on Your Education

Follow This Company

Job Description

Position Summary:

Andexxa is a licensed product and indicated for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to uncontrolled bleeding. Andexanet alfa (Andexxa) is manufactured using a sequence of chromatography steps and captured using affinity chromatography. Continued process development is necessary for improving product quality and robustness.

* This intern position will provide the student with the opportunity to learn protein purification and characterization methods. To improve product quality, the wash sequence of the affinity step will be evaluated for impurity (host cell proteins, DNA, etc.) removal.
* Manage contract and purchase order lifecycle for applicable transactions including reconciliations and mismatch resolution, contract renewal dates, adherence to contract terms and payment schedule; coordinate

Knowledge, Skills, Abilities and Requirements

* Currently pursuing a Bachelors or Masters degree in Life Sciences
* Completed college coursework in biology, biochemistry or other related fields
* Housing and transportation are the responsibility of the intern
* Must be returning to school for Fall term

Contact Us:

Our Company overview and history : https://www.portola.com/

About Portola Pharmaceuticals

Portola discovers and develops innovative therapeutics based on targets with established proof of concept that are designed to provide significant advances over current treatments for cardiovascular disease and autoimmune/inflammatory diseases. Portola scientists have successfully collaborated for over 15 years on the discovery and development of novel small molecule agents targeting platelets, coagulation pathways and protein kinases. Our team was instrumental in the discovery, development and commercialization of the leading GP IIb-IIIa inhibitor, INTEGRILIN® (eptifibatide). Portola's pipeline includes both proprietary and partnered products. In thrombosis, Portola has independently initiated a Phase 3 study of its lead molecule, betrixaban, a long-acting, oral, direct Factor Xa inhibitor. Portola plans to file an IND for its betrixaban companion product, PRT4445, a recombinant Factor Xa inhibitor antidote. In inflammation, the company is collaborating with Biogen Idec to develop highly selective, novel oral Spleen Tyrosine Kinase (Syk)-specific kinase inhibitors, including the lead molecule, PRT2607, for the treatment of various autoimmune and inflammatory diseases, and back up compounds. In addition, Portola's broad chemistry capability has led to the discovery of potent, oral dual inhibitors of Syk and Janus Kinase (JAK) for chronic autoimmune indications and oncology.